New A.i.d.s. Vaccine Boosts Immune System (Press, 18 October 1989)

An experimental AIDS vaccine has shown promising results in stimulating the immune system of individuals already infected with the AIDS virus, marking a significant breakthrough in treatment approaches. This development, reported on 18 October 1989, indicates that individuals who carry the human immunodeficiency virus (HIV) may potentially benefit from vaccination even before they exhibit symptoms of the disease. Franklin Volvovitz, chairman of MicroGeneSys Inc., the company behind the vaccine, expressed optimism about the findings, highlighting the vaccine's potential to modify the immune response in those chronically infected with HIV. Research conducted by a team from the United States Army revealed evidence of immune system responses in a small group of vaccinated individuals who received MicroGeneSys's genetically engineered vaccine, Vax Syn HIV-1. This information was shared during a meeting hosted by the National Cooperative Vaccine Development Group for AIDS in Florida. Dr. Robert R. Redfield, the team leader from the Walter Reed Army Institute of Research, described the therapeutic potential of HIV vaccines in treating early HIV infections as very encouraging. Amid these findings, the statement from MicroGeneSys noted that there were no observed toxic side effects in the vaccinated individuals, further supporting the vaccine's promise as a non-toxic treatment for early-stage AIDS patients. This research brings hope for improved management of HIV infections and highlights the importance of ongoing vaccine development efforts in the fight against AIDS.

The text on this page is created, in the most part, using Generative AI and so may contain errors or omissions. It is supplied to you without guarantee or warranty of correctness. If you find an error or would like to make a content suggestion please get in contact

The text on this page is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 New Zealand